Table 1.
Modification | Property | Example | Reference |
---|---|---|---|
Truncation of full-length enzyme | Increased catalytic ability and solubility | CHAPk | Horgan et al. [19] |
Fusion of EADs with CBDs of different endolysins | Increased catalytic ability and solubility | ClyS | Daniel et al. [20] |
Increased catalytic ability and broader lytic spectrum | SA2-E-Lyso-SH3b, SA2-E-LysK-SH3b | Schmelcher et al. [21] | |
Thermostability | PlyGVE2CpCWB | Swift et al. [22] | |
Fusion of virion-associated lysin with CBD of endolysin | Increased efficacy | EC300 | Proença et al. [23] |
Endolysin fusion with OMP | Increased efficacy towards Gram-negative bacteria | OBPgp279, PVP-SE1g-146 | Briers et al. [24] |
Endolysin fusion with AMP | Increased efficacy towards Gram-negative bacteria | Art-175 | Briers et al. [25] |
Truncation and site-directed mutagenesis | AMP development | LysAB2 | Peng et al. [26] |
EAD: enzymatically-active domain; CBD: cell wall-binding domain; OMP: outer-membrane permeabilizer; AMP: antimicrobial peptide.